Hyperosmolar Hyperglycemic State Medical Services in China

Hyperosmolar Hyperglycemic State (HHS) is a life-threatening acute metabolic complication of diabetes mellitus, predominantly occurring in patients with type 2 diabetes. It is characterized by extreme hyperglycemia (typically serum glucose >600 mg/dL), profound dehydration, elevated serum osmolality (>320 mOsm/kg), and absence of significant ketoacidosis (pH ≥7.30 and serum bicarbonate ≥18 mmol/L). Unlike diabetic ketoacidosis (DKA), HHS develops more insidiously—often over days to weeks—and reflects a severe deficit in effective circulating volume coupled with relative insulin sufficiency to suppress lipolysis but insufficient to prevent hyperglycemia. Pathogenesis centers on a combination of relative insulin deficiency, marked counterregulatory hormone excess (e.g., cortisol, catecholamines, glucagon), and impaired renal glucose clearance, frequently triggered by precipitating events such as infection (e.g., pneumonia, urinary tract infection), myocardial infarction, stroke, nonadherence to antihyperglycemic therapy, or use of diabetogenic medications (e.g., corticosteroids, thiazides, atypical antipsychotics). Dehydration worsens due to osmotic diuresis, leading to hypovolemic shock, altered mental status (ranging from confusion to coma), and multiorgan dysfunction—including acute kidney injury, rhabdomyolysis, and thromboembolic events. Epidemiologically, HHS carries higher mortality (10–20%) than DKA, especially among older adults (>65 years), with incidence estimated at 1–2 cases per 1,000 person-years among individuals with type 2 diabetes. Risk factors include advanced age, preexisting renal impairment, cognitive decline, limited access to healthcare, socioeconomic disadvantage, and comorbid conditions such as heart failure or dementia. Notably, up to one-third of HHS cases occur in previously undiagnosed diabetes. Quality of life impact is substantial: survivors often experience prolonged functional decline, increased dependency, cognitive deficits post-encephalopathy, recurrent hospitalizations, and heightened caregiver burden. Psychological sequelae—including anxiety, depression, and diabetes-related distress—are common, particularly when HHS results from treatment nonadherence or health literacy gaps. Early recognition hinges on vigilance for subtle symptoms: polyuria, profound thirst, dry mucous membranes, decreased skin turgor, lethargy, visual disturbances, and progressive neurologic changes. Delayed presentation significantly worsens prognosis; thus, patient education, community screening, and timely primary care referral are critical preventive strategies. In China, rising prevalence of type 2 diabetes—especially in aging urban and rural populations—has intensified HHS surveillance and standardized endocrine protocols across tertiary hospitals.

Hyperosmolar Hyperglycemic State (HHS) is a life-threatening endocrine emergency characterized by severe hyperglycemia (typically >600 mg/dL), profound hyperosmolality (>320 mOsm/kg), and minimal or absent ketosis. Unlike diabetic ketoacidosis (DKA), HHS occurs predominantly in older adults with type 2 diabetes, often precipitated by infection, myocardial infarction, stroke, medications (e.g., corticosteroids, thiazides), or impaired access to water. Mortality remains high—10–20%—necessitating prompt, protocol-driven management in an intensive care or specialized endocrinology unit.

Conservative treatment forms the cornerstone of HHS management and must be initiated immediately upon diagnosis. The primary goals are gradual correction of dehydration, controlled reduction of serum glucose, restoration of electrolyte balance, and identification and treatment of underlying precipitants. Fluid resuscitation begins with isotonic saline (0.9% NaCl) at 15–20 mL/kg over the first hour (≈1–1.5 L), followed by adjusted infusion rates based on hemodynamic status, urine output, and serum sodium trends. Subsequent fluid choice depends on corrected sodium: if normal or low, 0.45% saline is preferred; if elevated, isotonic saline continues cautiously. Total fluid deficits average 8–12 L and are replaced over 24–48 hours—not faster—to avoid cerebral edema, especially in elderly patients with chronic hyperglycemia and adaptive neuronal osmolyte shifts. Close monitoring includes hourly vital signs, strict intake/output, neurological assessments, serum glucose every 1–2 hours initially, and electrolytes (Na⁺, K⁺, Cl⁻, Mg²⁺, PO₄³⁻) every 2–4 hours. Central venous pressure or invasive hemodynamic monitoring may be warranted in patients with cardiac comorbidities.

Medication therapy centers on intravenous regular insulin infusion, initiated only after initial fluid resuscitation (typically after 1–2 hours) and once potassium is confirmed ≥3.3 mmol/L. A bolus is not recommended; instead, a continuous infusion at 0.05–0.1 units/kg/hour is titrated to achieve a glucose decline of 50–70 mg/dL per hour. Rapid glucose drops (<50 mg/dL/h) increase cerebral edema risk. When glucose reaches ~250–300 mg/dL, dextrose-containing fluids (e.g., 5% dextrose in 0.45% saline) are added to maintain glycemia at 200–250 mg/dL while continuing insulin to suppress lipolysis and resolve hyperosmolality. Potassium replacement is mandatory—even with normal serum levels—due to intracellular shifts during insulin therapy and volume repletion; typical requirements range from 20–40 mmol/hour, guided by serial measurements and ECG. Bicarbonate is rarely indicated (only if pH <6.9 with hemodynamic instability) and contraindicated in routine HHS due to risks of paradoxical CNS acidosis and hypokalemia. Prophylactic anticoagulation (e.g., enoxaparin) is strongly recommended given the prothrombotic state and high risk of venous thromboembolism.

Surgical treatment has no direct role in HHS pathophysiology and is not indicated for the metabolic derangement itself. However, urgent surgical intervention may be required for identified precipitants—for example, cholecystectomy for acute cholangitis, drainage of empyema or abscess, debridement of necrotizing fasciitis, or revascularization in acute limb ischemia. In such cases, perioperative glycemic management follows HHS protocols with intensified monitoring, stress-dose steroid coverage if applicable, and multidisciplinary coordination between endocrinology, surgery, and critical care. Elective procedures are deferred until full metabolic stabilization, typically ≥48–72 hours post-resolution of hyperosmolality and return to baseline functional status.

Treatment advantages in China stem from integrated, protocolized care within tiered healthcare systems and rapid adoption of evidence-based guidelines. Major tertiary hospitals—especially those affiliated with universities and designated as National Clinical Research Centers for Metabolic Diseases—employ standardized HHS pathways aligned with ADA and Chinese Diabetes Society (CDS) consensus statements. Real-time electronic health record alerts trigger automatic nursing protocols for glucose/electrolyte monitoring and insulin titration. Widespread availability of point-of-care osmolarity testing (via calculated or measured serum osmolality) and rapid HbA1c assays enables timely phenotyping. Moreover, China’s national insulin supply chain ensures uninterrupted access to high-quality human and rapid-acting analog insulins, even in remote regions via the 'Healthy China 2030' logistics network. Tele-endocrinology consults bridge gaps for county-level hospitals, allowing immediate specialist input. Importantly, China’s emphasis on geriatric endocrinology—given its rapidly aging population—has fostered expertise in managing frailty, polypharmacy, and atypical presentations common in elderly HHS patients, reducing iatrogenic complications such as overhydration or hypokalemia.

Recovery advice emphasizes structured transition and long-term prevention. Patients should remain hospitalized for ≥24 hours after achieving stable osmolality (<315 mOsm/kg), normoglycemia (140–180 mg/dL), and resolution of mental status changes. Upon discharge, all patients require comprehensive diabetes education: recognition of early symptoms (polyuria, confusion, lethargy), sick-day rules (never omitting insulin, checking glucose/ketones more frequently, maintaining hydration), and individualized glycemic targets. A follow-up visit with an endocrinologist within 72 hours is standard; home glucose monitoring logs and medication reconciliation are reviewed. Long-term strategies include optimizing outpatient regimens—often transitioning to basal-bolus insulin or GLP-1 receptor agonists with renal/hepatic safety profiles—and addressing modifiable risk factors (hypertension, dyslipidemia, smoking). Caregiver training is essential for cognitively impaired or homebound patients. Annual screening for complications (retinopathy, nephropathy, neuropathy) and vaccination updates (pneumococcal, influenza, COVID-19) are reinforced. Psychosocial support—including depression screening and nutrition counseling by certified diabetes educators—is embedded in recovery programs across leading Chinese centers, recognizing that recurrent HHS correlates strongly with socioeconomic vulnerability, health literacy gaps, and untreated depression. With rigorous adherence to these measures, recurrence rates can be reduced by over 60%.